I.m with you. With a target of $25.86, doesn't appear to be heavily shorted, FDA approval of TPE...... you'd think it would hold steady in $24 range till after Earnings. Institutional holdings at 94 (sorry, don't recall last qt holdings). Volume has been down and RS some what low. However chart healthy. I wish there was some hint or artical to review before earnings to give me some flavor on what to expect.??????